Sunstone Therapies Announces Publication of Positive Data on Use of Psilocybin Therapy for Patients with Cancer and Major Depression Disorder, in JAMA Oncology

Phase 2 data shows sustained response in 80% of patients and 50% of patients in full remission of depressive symptoms Use of group setting and 1:1 patient to therapist ratio has potential to increase accessibility of psilocybin therapy for patients with cancer and depression, and other indications Rockville, Maryland, April 13, 2023 – Sunstone Therapies, a leader in the development of clinical…


The product has been added to your cart.

Continue shopping View Cart